Five things to know:
1. Fourth-quarter revenue is projected to be within the range of $46.2 million to $46.6 million, representing 6 percent to 7 percent growth compared to the same period last year.
2. For the fourth quarter, the company expects spinal implants revenue to increase by between 7 percent and 8 percent and orthobiologics revenue to rise between 6 percent and 7 percent year over year.
3. Fourth-quarter international revenue is projected to decrease 3 percent to about $4.3 million.
4. U.S. sales saw year-over-year growth in November and December, but at a lower rate than October. SeaSpine launched five products in the fourth quarter.
5. As of Dec. 31, cash, cash equivalents and short-term investments were about $77 million. SeaSpine had no outstanding debt under its credit facility.
More articles on devices:
HOPCo, Ascension joint venture spine hospital opens in Florida; Georgia expansion planned
Stryker makes 1st acquisition of 2021: 4 details
As bundle participation declines, orthopedics looks to increased risk sharing and population health
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
